X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (175) 175
index medicus (125) 125
oncology (111) 111
hematology (78) 78
aged (68) 68
middle aged (66) 66
imatinib mesylate (65) 65
female (64) 64
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (60) 60
protein kinase inhibitors - therapeutic use (60) 60
adult (59) 59
treatment outcome (59) 59
male (57) 57
chronic myelogenous leukemia (56) 56
article (53) 53
benzamides (47) 47
antineoplastic agents - therapeutic use (46) 46
pyrimidines - therapeutic use (44) 44
animals (43) 43
dasatinib (42) 42
chronic myeloid leukemia (41) 41
imatinib (41) 41
mutation (40) 40
abridged index medicus (39) 39
aged, 80 and over (37) 37
hematology, oncology and palliative medicine (37) 37
piperazines - therapeutic use (36) 36
chronic myeloid-leukemia (35) 35
hemic and lymphatic diseases (34) 34
research (32) 32
bcr-abl (31) 31
prognosis (28) 28
tyrosine kinase inhibitor (27) 27
leukemia (26) 26
young adult (26) 26
adolescent (25) 25
care and treatment (25) 25
mice (25) 25
leukemia, myelogenous, chronic, bcr-abl positive - genetics (24) 24
protein kinase inhibitors - pharmacology (24) 24
protein-tyrosine kinases - antagonists & inhibitors (24) 24
cancer (23) 23
drug therapy (23) 23
nilotinib (23) 23
interferon-alpha (22) 22
cml (21) 21
therapy (21) 21
tyrosine kinase inhibitors (21) 21
antineoplastic agents - pharmacology (19) 19
drug resistance, neoplasm (19) 19
genetic aspects (19) 19
resistance (19) 19
pyrimidines - adverse effects (18) 18
fusion proteins, bcr-abl - genetics (17) 17
janus kinase 2 - genetics (17) 17
apoptosis - drug effects (16) 16
disease-free survival (16) 16
pyrimidines - administration & dosage (16) 16
cell line, tumor (15) 15
clinical trials as topic (15) 15
dosage and administration (15) 15
leukemia, myeloid, chronic-phase - drug therapy (15) 15
myeloproliferative disorders (15) 15
pharmacology & pharmacy (15) 15
pyrimidines - pharmacology (15) 15
acute lymphoblastic-leukemia (14) 14
antineoplastic agents - administration & dosage (14) 14
cytogenetic responses (14) 14
follow-up studies (14) 14
health aspects (14) 14
janus kinase 2 - antagonists & inhibitors (14) 14
polycythemia-vera (14) 14
survival analysis (14) 14
thiazoles - therapeutic use (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
blast crisis (13) 13
chemistry (13) 13
chronic-phase (13) 13
disease progression (13) 13
human necessities (13) 13
hygiene (13) 13
leukemia, myelogenous, chronic, bcr-abl positive - mortality (13) 13
medical or veterinary science (13) 13
metallurgy (13) 13
myelofibrosis (13) 13
preparations for medical, dental, or toilet purposes (13) 13
risk factors (13) 13
tyrosine kinase jak2 (13) 13
bcr-abl1 (12) 12
gene mutations (12) 12
leukemia, myeloid, acute - drug therapy (12) 12
medicine, general & internal (12) 12
physiological aspects (12) 12
piperazines - administration & dosage (12) 12
acute myeloid-leukemia (11) 11
antineoplastic agents - adverse effects (11) 11
beer (11) 11
biochemistry (11) 11
clinical trials and observations (11) 11
enzymology (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/2011, Volume 108, Issue 29, pp. 11995 - 12000
Journal Article
Oncotarget, ISSN 1949-2553, 07/2018, Volume 9, Issue 52, pp. 29843 - 29844
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 3/2014, Volume 111, Issue 9, pp. 3550 - 3555
The acquisition of mutations within the BCR-ABL1 kinase domain is frequently associated with tyrosine kinase inhibitor (TKI) failure in chronic myeloid... 
Leukemia | Alleles | Cytogenetics | Molecular dynamics | Chronic myeloid leukemia | Inhibitory concentration 50 | Genetic mutation | Blood | Free energy | Resistance mechanisms | Ponatinib resistance | Compound mutation | CHRONIC MYELOGENOUS LEUKEMIA | CHRONIC PHASE | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | BCR-ABL INDEPENDENCE | DOMAIN MUTATIONS | CHRONIC MYELOID-LEUKEMIA | MESYLATE RESISTANCE | SELECTIVE INHIBITOR | ponatinib resistance | IMATINIB | CYTOGENETIC RESPONSE | compound mutation | Fusion Proteins, bcr-abl - chemistry | Piperazines | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Models, Molecular | DNA Primers - genetics | Imidazoles - pharmacology | Pyridazines - pharmacology | Mutation - genetics | Imatinib Mesylate | Molecular Dynamics Simulation | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Pyrimidines | Analysis of Variance | Cloning, Molecular | Polymerase Chain Reaction | Benzamides | Imidazoles - therapeutic use | Pyridazines - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Care and treatment | Molecular genetics | Gene mutations | Myelocytic leukemia | Physiological aspects | Genetic research | Genetic aspects | Nonlymphoid leukemia | Research | Phosphotransferases | Health aspects | Cancer | Biological Sciences
Journal Article
Cancer Cell, ISSN 1535-6108, 06/2012, Volume 21, Issue 6, pp. 793 - 806
Studies on the role of mutation in breast cancer response to chemotherapy are conflicting. Here, we show that, contrary to dogma, MMTV- mammary tumors with p53... 
P53 MUTATIONS | ONCOLOGY | TP53 STATUS | IN-VIVO | DNA-DAMAGE | CELL-CYCLE ARREST | ANTHRACYCLINE-RESISTANCE | TUMOR-CELLS | TUMORIGENESIS | TRANSGENIC MICE | MAMMARY | CELL BIOLOGY | Wnt1 Protein - genetics | Antibiotics, Antineoplastic - pharmacology | Apoptosis - drug effects | Humans | Aging - drug effects | Apoptosis - genetics | Mammary Neoplasms, Experimental - genetics | Tumor Suppressor Protein p53 - genetics | Cyclin-Dependent Kinase Inhibitor p21 - genetics | Aging - genetics | RNA Interference | Mammary Neoplasms, Experimental - pathology | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Tumor Burden - genetics | Gene Expression Regulation, Neoplastic - drug effects | Cytokines - genetics | Mammary Neoplasms, Experimental - drug therapy | Cytokines - metabolism | Mice, Inbred C57BL | Tumor Suppressor Protein p53 - metabolism | Mice, Transgenic | Treatment Outcome | Reverse Transcriptase Polymerase Chain Reaction | Breast Neoplasms - drug therapy | Blotting, Western | Mice, Knockout | Animals | Breast Neoplasms - genetics | Tumor Burden - drug effects | Breast Neoplasms - pathology | Cell Line, Tumor | Mice | Mutation | Mammary Tumor Virus, Mouse - genetics | Doxorubicin - pharmacology | Medical colleges | Care and treatment | Patient outcomes | Leukemia | Oncology, Experimental | Genes | Breast cancer | Research | Chemotherapy | Gene mutations | Cell death | Universities and colleges | Tumor proteins | Tumors | Cancer | Apoptosis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2019, Volume 381, Issue 3, pp. e6 - 1737
To the Editor: Raje et al. (May 2 issue) 1 describe the safety profile and antitumor activity of the anti–B-cell maturation antigen (BCMA) chimeric antigen... 
MEDICINE, GENERAL & INTERNAL | Antigens | Antitumor activity | Lymphocytes T | Lymphocytes B | Patients | Multiple myeloma
Journal Article
Journal Article
Leukemia & lymphoma, 01/2019, p. 1
Journal Article
Journal Article
The New England journal of medicine, 03/2018, Volume 378, Issue 11, p. 1065
Journal Article
American Journal of Hematology, ISSN 0361-8609, 12/2013, Volume 88, Issue 12, pp. 1024 - 1029
Most patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with tyrosine kinase inhibitors (TKI) achieve complete cytogenetic response... 
CHRONIC MYELOGENOUS LEUKEMIA | INTERFERON-ALPHA | THERAPY | CML | DASATINIB | HEMATOLOGY | ALPHA PLUS CYTARABINE | IMATINIB MESYLATE | DISCONTINUATION | NILOTINIB | REMISSION | Humans | Middle Aged | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Thiazoles - therapeutic use | Biomarkers, Tumor | RNA, Neoplasm - blood | Young Adult | Benzamides - therapeutic use | Fusion Proteins, bcr-abl - blood | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Neoplasm Proteins - genetics | Real-Time Polymerase Chain Reaction | Dasatinib | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Treatment Outcome | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Disease-Free Survival | Fusion Proteins, bcr-abl - genetics | RNA, Messenger - blood | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Survival Analysis | Neoplasm Proteins - blood | Aged | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Leukemia, Myeloid, Chronic-Phase - genetics | Tyrosine | Phenols | Care and treatment | Chronic myeloid leukemia | Analysis | tyrosine kinase inhibitors | chronic myeloid leukemia | molecular response | BCR-ABL
Journal Article